OncoMatch/Clinical Trials/NCT07003542
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Is NCT07003542 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sitagliptin for glioblastoma.
Treatment: Sitagliptin — The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer. Sitagliptin is an investigational drug for this condition that works by inhibiting an enzyme called dipeptidyl peptidase 4 (DPP-4), which MDSCs rely on to enter the brain and function. While sitagliptin is FDA-approved for diabetes treatment, its use in glioblastoma is investigational (experimental).
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE 4 (WHO)
Grade: 4 (WHO)
WHO grade 4 glioma (including tumors with molecularly defined grade 4 astrocytoma)
Prior therapy
Cannot have received: gliptin (sitagliptin)
Participants must not have received sitagliptin or other gliptins.
Cannot have received: investigational agent
Participants receiving any other investigational agents.
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dl; Absolute neutrophil count ≥ 1,500/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Calculated creatinine clearance > 50 mL/min or creatinine < 1.5x institutional ULN
Liver function
Total bilirubin < 1.5x institutional ULN; AST (SGOT) ≤ 3x institutional ULN; ALT (SGPT) ≤ 3x institutional ULN
adequate organ function and laboratory parameters within 21 days of study entry as defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify